Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Mitapivat (Pyrukynd)

Notes:

• Quantity Limits: Yes

<u>Initiation (new start) criteria</u>: Formulary **mitapivat (Pyrukynd)** will be covered on the prescription drug benefit for <u>6 months</u> when the following criteria are met:

- Patient is at least 18 years of age
- Patient has a diagnosis of Pyruvate Kinase Deficiency (PKD) AND hemolytic anemia
- Medication is prescribed by a hematologist/oncologist
- Patient is NOT homozygous for the R479H mutation
- Patient has 2 mutant alleles in the PKLR gene and at least 1 of them is a missense mutation
- Patient is transfusion-dependent (required 6 or more transfusions in the past 365 days) OR has hemoglobin less than or equal to 10 g/dL

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously</u>: Formulary mitapivat (Pyrukynd) will be covered on the prescription drug benefit for 6 months when the following criteria are met:

- Patient is at least 18 years of age
- Patient has a diagnosis of Pyruvate Kinase Deficiency (PKD) AND hemolytic anemia
- Medication is prescribed by a hematologist/oncologist

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Formulary <u>mitapivat</u> (Pyrukynd)
will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria
are met:

- Patient is at least 18 years of age
- Patient has a diagnosis of Pyruvate Kinase Deficiency (PKD) AND hemolytic anemia
- Medication is prescribed by a hematologist/oncologist

<u>Continued use criteria (6 months after initiation)</u>: Formulary <u>mitapivat (Pyrukynd)</u> will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

• Patient is at least 18 years of age

kp.org

Revised: 02/09/2023 Effective: 04/06/2023 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest




Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Mitapivat (Pyrukynd)

- Patient has a diagnosis of Pyruvate Kinase Deficiency (PKD) AND hemolytic anemia
- Medication is prescribed by a hematologist/oncologist
- Decrease in number of red blood cell units transfused of 33% or greater compared to baseline* -OR- increase in hemoglobin level of 1.5 g/dL or greater compared to baseline -OR- mitapivat (Pyrukynd) dose was increased by the prescriber in the past 4 weeks

kp.org

Revised: 02/09/2023 Effective: 04/06/2023





^{*}Baseline period for transfusions is defined as the 6-month period prior to initiation of mitapivat (Pyrukynd)